Clinical trial · Interventional
Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma
Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves the use of chemotherapy as the therapeutic mainstay. Platinum-etoposide regimens (such as cisplatin-etoposide) are the most commonly used chemotherapeutic regimen, which is delivered intravenously in the standard three-weekly intervals. Recent interest in oral metronomic chemotherapy has arisen, especially due to its beneficial effects in delaying disease progression among heavily pre-treated patients with various malignancies. This study attempts to combine the use of metronomic chemotherapy concurrently during standard intravenous chemotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung | Lung Neoplasm | PROBABILISTIC | 0.70 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Squamous Cell Carcinoma of the Lung | Lung Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravenous Cisplatin & etoposide | Drug | — | UNRESOLVED |
| Intravenous Cisplatin & etoposide along with oral cyclophosphamide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard intravenous chemotherapy
- description
- Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
- interventionNames
- Drug: Intravenous Cisplatin & etoposide
- type
- EXPERIMENTAL
- label
- Intravenous with metronomic chemotherapy
- description
- Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
- interventionNames
- Drug: Intravenous Cisplatin & etoposide along with oral cyclophosphamide
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathologically proven squamous cell carcinoma of the lung * Surgically unresectable or metastatic disease Exclusion Criteria: * Severe life limiting diabetes, hypertension or cardiac co-morbidities * Co-existing tuberculosis * Brain metastases at presentation * Non-consenting patients * Previously treated with any regimen of chemotherapy for existing or previous malignancy
References
Publications (0)
Data not yet available